ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc.

November 10, 2005 12:53 ET

ProMetic to Release Third Quarter 2005 Financial Results On Monday, November 14, 2005

MONTREAL, QUEBEC--(CCNMatthews - Nov. 10, 2005) - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI.SV) announces that the Company will release its third quarter and 2005 financial results on Monday, November 14, 2005 after market close. ProMetic will host a conference call on Tuesday, November 15, 2005 at 9:00 a.m. (EST).

Conference Call

Participants are invited to attend by connecting 10 minutes prior to the call to one of the following: 1-877-461-2815 (North America) or 416-695-6371 (international). The conference call will be webcast live on the Company's website at To access the archived conference call, dial 1-866-518-1010 (North America) and 416-695-5275 (international) available until November 29, 2005.

About ProMetic Life Sciences

ProMetic Life Sciences Inc. is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of inflammation and cancer. Its drug discovery platform is focussed on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D and manufacturing facilities in the UK and business development activities in the US, Europe, Asia and MENA countries (Middle East and North Africa).

Additional information is available on the Company's website at

This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to the Company's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products and to obtain contracts for its products and services and commercial acceptance of advanced affinity separation technology. Shareholders are cautioned that these statements are predictions and these actual events or results may differ materially from those anticipated in these forward-looking statements.

Contact Information